- Home
- SJT vs VYGR Comparison
SJT vs VYGR Comparison
Compare SJT & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- VYGR
- Stock Information
- Founded
- SJT 1980
- VYGR 2013
- Country
- SJT United States
- VYGR United States
- Employees
- SJT N/A
- VYGR 172
- Industry
- SJT Oil & Gas Production
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- SJT Energy
- VYGR Health Care
- Exchange
- SJT Nasdaq
- VYGR Nasdaq
- Market Cap
- SJT 282.0M
- VYGR 232.4M
- IPO Year
- SJT N/A
- VYGR 2015
- Fundamental
- Price
- SJT $5.69
- VYGR $4.24
- Analyst Decision
- SJT
- VYGR Strong Buy
- Analyst Count
- SJT 0
- VYGR 7
- Target Price
- SJT N/A
- VYGR $16.17
- AVG Volume (30 Days)
- SJT 216.6K
- VYGR 453.1K
- Earning Date
- SJT 11-13-2025
- VYGR 11-10-2025
- Dividend Yield
- SJT N/A
- VYGR N/A
- EPS Growth
- SJT N/A
- VYGR N/A
- EPS
- SJT N/A
- VYGR N/A
- Revenue
- SJT $24,557.00
- VYGR $31,316,000.00
- Revenue This Year
- SJT N/A
- VYGR N/A
- Revenue Next Year
- SJT N/A
- VYGR $107.10
- P/E Ratio
- SJT N/A
- VYGR N/A
- Revenue Growth
- SJT N/A
- VYGR N/A
- 52 Week Low
- SJT $3.66
- VYGR $2.65
- 52 Week High
- SJT $7.22
- VYGR $7.44
- Technical
- Relative Strength Index (RSI)
- SJT 43.14
- VYGR 46.79
- Support Level
- SJT $5.90
- VYGR $4.05
- Resistance Level
- SJT $6.55
- VYGR $4.40
- Average True Range (ATR)
- SJT 0.25
- VYGR 0.25
- MACD
- SJT -0.05
- VYGR 0.00
- Stochastic Oscillator
- SJT 14.14
- VYGR 72.03
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.